Antibodies Causing Epilepsy Syndromes: The ACES Study.
ACES
1 other identifier
observational
582
1 country
8
Brief Summary
The Antibodies Causing Epilepsy Syndromes (ACES) Study is a observational cohort study focusing on detection of auto-immune epilepsy in patients with epilepsy of unknown origin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2014
Longer than P75 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
June 7, 2016
CompletedFirst Posted
Study publicly available on registry
June 16, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedJuly 28, 2022
July 1, 2022
5 years
June 7, 2016
July 27, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
frequency of patients with known and novel antibodies
detection of specific known and novel, currently unknown, auto-antibodies by immunohistochemistry, live hippocampal neuron cultures and cell-based assay
3 year
Secondary Outcomes (3)
modified Rankin scale
1 year
Seizure frequency
1 year
Treatment response
3 months
Study Arms (2)
acquired chronic, focal, epilepsy
patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
new onset epilepsy
patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
Interventions
Eligibility Criteria
Adults with acquired chronic focal epilepsy without known cause or new onset status epilepticus or new onset seizures with signs of encephalitis and unknown cause.
You may qualify if:
- Age of 18 and older.
- Status epilepticus or new onset seizures with signs of limbic encephalitis (clinical picture, MRI (FLAIR abnormalities), EEG abnormalities or CSF findings (CSF pleocytosis, increased IgG index, oligoclonal bands), or:
- Patients with acquired chronic focal epilepsy with an unknown cause.
You may not qualify if:
- Children
- Epilepsy with known cause
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Erasmus Medical Centerlead
- Nationaal Epilepsie Fondscollaborator
Study Sites (8)
Epilepsiecentrum Kempenhaeghe
Heemstede, Netherlands
Stichting Epilepsie Instelling Nederland (SEIN)
Heemstede, Netherlands
Academic Hospital Maastricht
Maastricht, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands
Maasstad Hospital
Rotterdam, Netherlands
Haga Hospital
The Hague, Netherlands
St. Elisabeth Hospital
Tilburg, Netherlands
UMCU
Utrecht, Netherlands
Biospecimen
serum and (if available) CSF
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Maarten J Titulaer, MD,PhD
Erasmus Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD. PhD.
Study Record Dates
First Submitted
June 7, 2016
First Posted
June 16, 2016
Study Start
December 1, 2014
Primary Completion
December 1, 2019
Study Completion
December 1, 2020
Last Updated
July 28, 2022
Record last verified: 2022-07